GE HealthCare Expands in Japan with Full Acquisition of Nihon Medi-Physics

2025-03-31 digitalcare

Chicago, Monday, 31 March 2025.
GE HealthCare completed the acquisition of Nihon Medi-Physics, enhancing its position in radiopharmaceuticals with better access to advanced imaging technology crucial for disease diagnosis.

Strategic Expansion and Market Impact

The acquisition, announced on March 31, 2025, marks a significant milestone as GE HealthCare obtains full ownership of NMP by acquiring Sumitomo Chemical’s 50% stake [1][3]. NMP, established in 1973, has demonstrated strong market performance with revenues reaching 28.2B JPY (approximately $183M) in 2023 [1]. This strategic move builds upon GE HealthCare’s existing presence in Japan’s radiopharmaceutical sector, positioning the company to enhance its molecular imaging capabilities across neurology, cardiology, and oncology procedures [1].

Leadership and Integration Plans

Kevin O’Neill, who currently serves as President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will assume the additional role of President of NMP [1][5]. Under the new leadership structure, the integration of NMP’s technologies into GE HealthCare’s systems is scheduled to commence in Q3 2025 [3]. This integration aims to accelerate the development and accessibility of next-generation radiopharmaceuticals, particularly enhancing capabilities in Single Photon Emission Computed Tomography (SPECT) imaging [3].

Future Outlook and Market Positioning

The acquisition represents a strategic enhancement of GE HealthCare’s position in the global healthcare market, particularly in advanced molecular imaging solutions [3]. The company anticipates that this transaction will maintain neutral Adjusted EPS in the first year, with positive growth projected thereafter [1]. This expansion aligns with GE HealthCare’s broader strategy to strengthen its diagnostic capabilities and enhance patient access to advanced imaging technologies [1][3].

sources

acquisition radiopharmaceuticals